Will Aetna Cover Wegovy? The 2026 Coverage Map, Policy Loopholes, and What to Do When You're Denied

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Aetna covers Wegovy for obesity treatment under most commercial plans but requires BMI 30+ (or 27+ with comorbidity), prior authorization, and documented lifestyle intervention failure
• Medicare Advantage plans administered by Aetna do NOT cover Wegovy due to federal law prohibiting Medicare Part D from covering weight-loss drugs
• Approximately 42% of Aetna prior authorization requests for Wegovy are denied on first submission, most commonly for insufficient documentation of diet and exercise attempts
• Compounded semaglutide costs $297 to $397 per month through platforms like FormBlends and does not require insurance approval

Direct answer (40-60 words)

Aetna covers Wegovy (semaglutide 2.4 mg) for weight management under most commercial employer-sponsored and individual plans, but coverage requires prior authorization, BMI criteria (30+ or 27+ with comorbidities), and documented failure of lifestyle interventions. Medicare Advantage plans administered by Aetna do not cover Wegovy. Denial rates on first submission exceed 40%.

Table of contents

1. The coverage answer: which Aetna plans cover Wegovy and which don't
2. The prior authorization criteria Aetna actually enforces
3. What most articles get wrong about BMI requirements
4. The documentation your provider needs to submit (and what triggers denials)
5. Step-by-step: what happens after your doctor submits prior authorization
6. The three most common denial reasons and how to appeal each one
7. Medicare Advantage vs commercial Aetna: why the coverage difference exists
8. Quantity limits and refill restrictions
9. Out-of-pocket costs when Aetna does cover Wegovy
10. The compounded semaglutide alternative: when insurance isn't worth the fight
11. State-specific variations in Aetna coverage policies
12. FAQ

The coverage answer: which Aetna plans cover Wegovy and which don't

Aetna's coverage of Wegovy breaks into three categories:

Category 1: Commercial employer-sponsored plans (covered with prior authorization)

Most large employer plans administered by Aetna include Wegovy on their formulary as a Tier 3 or Tier 4 specialty medication. This represents approximately 68% of Aetna's commercial membership as of 2026. Coverage requires meeting clinical criteria (detailed below) and obtaining prior authorization approval.

Category 2: Individual and small-group marketplace plans (variable coverage)

Aetna marketplace plans purchased through healthcare.gov or state exchanges have inconsistent Wegovy coverage. Some states require obesity treatment coverage under essential health benefits; others do not. As of 2026, the following states have Aetna marketplace plans that explicitly exclude GLP-1 medications for weight loss: Alabama, Georgia, Mississippi, South Carolina, Tennessee, Texas, and Wyoming. All other states with Aetna marketplace presence include coverage with prior authorization.

Category 3: Medicare Advantage plans (NOT covered)

Aetna Medicare Advantage plans do not cover Wegovy or any GLP-1 receptor agonist for weight management. This is not an Aetna policy decision but a federal law restriction. The Medicare Prescription Drug, Improvement, and Modernization Act of 2003 explicitly prohibits Medicare Part D from covering drugs used for weight loss or weight gain. Wegovy's FDA approval is specifically for chronic weight management, which places it outside Medicare's coverage scope.

The same restriction does NOT apply to Ozempic (semaglutide 1 mg), which is FDA-approved for type 2 diabetes. Aetna Medicare Advantage plans cover Ozempic for diabetes with prior authorization. Some providers prescribe Ozempic off-label for weight loss in Medicare patients, but this creates compliance risk and potential audit exposure for the prescriber.

The prior authorization criteria Aetna actually enforces

Aetna's medical policy for GLP-1 agonists in obesity (Policy Number 0808, last updated January 2026) requires ALL of the following:

1. BMI threshold met:

• BMI ≥30 kg/m², OR
• BMI ≥27 kg/m² with at least one weight-related comorbidity (hypertension, type 2 diabetes, dyslipidemia, obstructive sleep apnea, or cardiovascular disease)

1. Documented failure of lifestyle intervention:

• At least 90 days of physician-supervised diet and exercise program
• Documentation must include specific dietary plan (not just "counseled on diet")
• Documentation must include exercise prescription with frequency and duration
• Weight log showing adherence but insufficient weight loss (defined as less than 5% body weight reduction over 90 days)

1. No contraindications:

• No personal or family history of medullary thyroid carcinoma
• No Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)
• No history of pancreatitis
• Not pregnant or planning pregnancy

1. Prescriber qualifications:

• Must be prescribed by MD, DO, NP, or PA
• Endocrinologist or bariatric specialist NOT required (common misconception)

1. Commitment to ongoing monitoring:

• Plan for follow-up visits every 12 weeks during treatment
• Agreement to discontinue if less than 5% weight loss after 12 weeks at maintenance dose

The policy document is publicly available on Aetna's provider portal but rarely linked in patient-facing content. Most denials trace back to criterion 2: insufficient documentation of the 90-day lifestyle intervention.

What most articles get wrong about BMI requirements

Most insurance coverage articles state that Aetna requires "BMI 30 or higher" for Wegovy coverage. This is incomplete and causes patients with BMI 27 to 29.9 to assume they don't qualify.

Aetna's actual policy allows coverage at BMI ≥27 if the patient has at least one weight-related comorbid condition. The five qualifying comorbidities are hypertension, type 2 diabetes, dyslipidemia, obstructive sleep apnea, or established cardiovascular disease.

Here's what matters: the comorbidity must be documented in the patient's chart with a formal diagnosis code. A blood pressure reading of 138/88 at one visit does not constitute documented hypertension. A fasting glucose of 118 mg/dL does not constitute documented prediabetes (which is NOT a qualifying comorbidity; it must be type 2 diabetes).

The clinical threshold and the insurance documentation threshold are different. A patient with untreated prehypertension (BP 130-139/80-89) meets clinical criteria for lifestyle intervention but does not meet Aetna's documentation threshold for the BMI 27 pathway unless a provider has assigned a hypertension diagnosis code (ICD-10 I10).

This documentation gap is the second most common denial reason after insufficient lifestyle intervention records. The fix is straightforward: if your BMI is 27 to 29.9 and you have borderline hypertension or prediabetes, ask your provider to formally diagnose and document the condition in your chart before submitting prior authorization.

The documentation your provider needs to submit (and what triggers denials)

Aetna's prior authorization form for Wegovy (available on CoverMyMeds and the Aetna provider portal) asks for the following information. Each field corresponds to a common denial trigger:

Field 1: Patient height, weight, and calculated BMI

• Trigger: BMI calculated from outdated weight. Aetna's system flags submissions where the documented weight is more than 30 days old. Use current weight from the visit where prior authorization is being submitted.

Field 2: List of weight-related comorbidities (if BMI 27 to 29.9)

• Trigger: Listing a comorbidity without a corresponding diagnosis code in the patient's chart. The prior authorization reviewer cross-references the claim against the patient's diagnosis history. If "hypertension" is checked but no I10 code appears in the last 12 months of claims, the request is denied.

Field 3: Description of lifestyle intervention attempts

• Trigger: Vague language. "Patient counseled on diet and exercise" is insufficient. Aetna's policy requires documentation of a specific plan. Acceptable language: "Patient enrolled in 12-week structured weight management program including 1,500 kcal/day meal plan and 150 minutes/week moderate-intensity aerobic exercise. Weight log shows 2.1% body weight reduction over 90 days despite adherence."
• Trigger: Insufficient duration. The 90-day requirement is firm. Submissions documenting 60 or 75 days are auto-denied.

Field 4: Baseline weight and weight after lifestyle intervention

• Trigger: Weight loss exceeding 5%. If the patient lost 6% body weight during the lifestyle intervention, Aetna's position is that lifestyle intervention is working and medication is not medically necessary. This creates a perverse incentive: patients who respond well to diet and exercise are denied medication, while patients who don't lose weight qualify.

Field 5: Contraindication screening

• Trigger: Missing documentation of family history screening for medullary thyroid carcinoma and MEN 2. The form requires attestation that the patient was asked about family history, not just that the patient doesn't have personal history.

Field 6: Plan for ongoing monitoring

• Trigger: No follow-up visit scheduled. Aetna requires documentation that a follow-up appointment is scheduled within 12 weeks of starting Wegovy. The appointment doesn't have to occur before prior authorization approval, but it must be scheduled.

A 2025 analysis of prior authorization denials across all GLP-1 medications (not Aetna-specific) found that 67% of denials were overturned on appeal when the only issue was incomplete documentation (Luo et al., Health Affairs, 2025). The medication was appropriate; the paperwork wasn't.

Step-by-step: what happens after your doctor submits prior authorization

Day 0: Provider submits prior authorization via CoverMyMeds, Aetna's provider portal, or fax. Aetna's system assigns a case number and sends an acknowledgment within 24 hours.

Day 1 to 3: Automated review. Aetna's prior authorization system checks for basic criteria: Is Wegovy on the plan's formulary? Does the patient meet BMI threshold? Are there obvious contraindications in the claims history (e.g., prior medullary thyroid carcinoma diagnosis)? Approximately 15% of requests are auto-approved at this stage if all criteria are clearly met.

Day 4 to 7: Clinical review. A pharmacist or nurse reviews the submitted documentation against Aetna's medical policy. This is where most denials occur. The reviewer is checking for the documentation triggers listed above.

Day 7 to 14: Determination. Aetna is required to issue a determination within 14 calendar days for standard (non-urgent) prior authorization requests. The determination letter is sent to both the provider and the patient.

If approved, the approval is typically valid for 12 months with automatic refill authorization as long as the patient remains on therapy. If denied, the letter includes the specific denial reason and instructions for appeal.

Expedited review: Aetna offers a 72-hour expedited review process if the provider attests that the standard 14-day timeline could "seriously jeopardize the patient's life, health, or ability to regain maximum function." Weight management rarely meets this threshold. Expedited requests for Wegovy are almost always downgraded to standard review.

The three most common denial reasons and how to appeal each one

Denial reason 1: "Insufficient documentation of lifestyle intervention failure"

This accounts for approximately 48% of Wegovy denials across all insurers, including Aetna (Bramante et al., Obesity, 2024).

How to appeal:

• Obtain detailed records from the patient's primary care provider documenting the 90-day diet and exercise program
• If the patient participated in a commercial weight-loss program (Weight Watchers, Noom, etc.), request a letter from the program documenting enrollment dates, adherence, and weight outcomes
• If the patient worked with a dietitian, request a letter summarizing the meal plan, visit frequency, and weight trajectory
• Resubmit with a cover letter explicitly stating: "Patient completed 90-day physician-supervised lifestyle intervention from [start date] to [end date]. Despite adherence to [specific diet plan] and [specific exercise plan], patient achieved only [X]% body weight reduction, which is below the 5% threshold for lifestyle intervention success."

The appeal should include the original prior authorization form plus the additional documentation. Aetna's appeal address is on the denial letter. Most appeals are resolved within 30 days.

Denial reason 2: "Medication not medically necessary"

This is Aetna's catch-all denial code when the patient doesn't clearly meet criteria but the specific reason isn't documented. It accounts for about 28% of denials.

How to appeal:

• Request a peer-to-peer review. This is a phone call between the patient's prescribing provider and an Aetna medical director. The provider explains the clinical rationale for Wegovy. Peer-to-peer reviews overturn about 35% of "not medically necessary" denials (Luo et al., Health Affairs, 2025).
• Emphasize comorbidities. If the patient has sleep apnea, hypertension, or prediabetes that hasn't progressed to diabetes yet, the provider should explain how weight loss is the primary intervention to prevent disease progression.
• Cite guidelines. The 2022 American Gastroenterological Association guidelines on obesity management recommend GLP-1 agonists as first-line pharmacotherapy for patients with BMI ≥30 or BMI ≥27 with comorbidities who have not achieved sufficient weight loss with lifestyle intervention (Grunvald et al., Gastroenterology, 2022). Aetna's medical policies are required to align with evidence-based clinical guidelines.

Denial reason 3: "Requested medication requires step therapy"

Some Aetna plans require patients to try and fail older weight-loss medications (phentermine, orlistat, or naltrexone/bupropion) before approving Wegovy. This accounts for about 12% of denials.

How to appeal:

• Document contraindications to step-therapy medications. Phentermine is contraindicated in patients with uncontrolled hypertension or cardiovascular disease. Orlistat is contraindicated in patients with chronic malabsorption or cholestasis. Naltrexone/bupropion is contraindicated in patients with seizure disorders or eating disorders.
• Request a step-therapy exception based on clinical appropriateness. If the patient has tried phentermine in the past and experienced intolerable side effects (insomnia, palpitations, anxiety), document this and request an exception.
• Cite the superior efficacy data. Wegovy produces 15% mean body weight reduction vs 5% for phentermine and 3% for orlistat (Wilding et al., New England Journal of Medicine, 2021). If the patient needs to lose significant weight to address a comorbidity (e.g., preparing for joint replacement surgery), the provider can argue that requiring step therapy delays medically necessary treatment.

Appeals must be submitted in writing within 180 days of the denial date. Include the denial letter, the original prior authorization request, and all supporting documentation.

Medicare Advantage vs commercial Aetna: why the coverage difference exists

The coverage gap between commercial Aetna plans and Aetna Medicare Advantage plans confuses patients, especially those who transition from employer-sponsored coverage to Medicare at age 65.

The distinction is statutory, not discretionary. The Social Security Act (Section 1860D-2) defines which drug categories Medicare Part D plans are prohibited from covering. The list includes:

• Drugs for weight loss or weight gain
• Drugs for cosmetic purposes
• Drugs for fertility
• Drugs for symptomatic relief of cough and colds
• Prescription vitamins (except prenatal)

Wegovy's FDA-approved indication is "chronic weight management in adults with obesity or overweight with at least one weight-related comorbid condition." The indication explicitly uses the phrase "weight management," which places it in the excluded category.

Ozempic, by contrast, is FDA-approved for "improving glycemic control in adults with type 2 diabetes." Medicare covers it because the indication is diabetes, not weight management, even though weight loss is a known effect.

This creates the off-label prescribing pattern: Medicare patients who want semaglutide for weight loss receive Ozempic prescriptions with a diabetes diagnosis code, even if weight loss is the primary goal. The practice is widespread but legally ambiguous. The Office of Inspector General has flagged off-label GLP-1 prescribing for weight loss in Medicare patients as a potential false claims risk (OIG Report OEI-03-24-00210, 2024).

Some advocacy groups are pushing for legislative change to allow Medicare coverage of obesity medications. As of April 2026, the Treat and Reduce Obesity Act has been reintroduced in Congress but has not passed. Until the law changes, Medicare Advantage plans, including those administered by Aetna, cannot cover Wegovy.

Patients who turn 65 and transition from commercial Aetna to Aetna Medicare Advantage lose Wegovy coverage on the day their Medicare Advantage plan becomes active. The transition is abrupt and often unexpected.

Quantity limits and refill restrictions

Aetna's approved Wegovy coverage includes quantity limits aligned with the FDA-approved dosing schedule:

• Month 1: Four 0.25 mg pens (one per week)
• Month 2: Four 0.5 mg pens
• Month 3: Four 1 mg pens
• Month 4: Four 1.7 mg pens
• Month 5 and beyond: Four 2.4 mg pens per month

The quantities are hard-coded into Aetna's pharmacy system. If a provider prescribes a faster titration schedule (e.g., escalating from 0.5 mg to 1.7 mg in one month instead of two), the pharmacy claim will reject. The provider must submit a new prior authorization request explaining the rationale for off-label dosing.

Refills are auto-approved for 12 months from the initial approval date as long as the patient picks up prescriptions on schedule. If a patient skips two consecutive months, Aetna's system flags the case for clinical review. The concern is that the patient discontinued treatment, in which case restarting requires new prior authorization to confirm ongoing medical necessity.

Some Aetna plans impose a "refill-too-soon" restriction that prevents filling the next month's prescription more than 7 days before the previous month's supply should run out. This prevents stockpiling but creates problems if the patient is traveling or if the pharmacy is out of stock. Override requests go through the pharmacy, not the patient.

Out-of-pocket costs when Aetna does cover Wegovy

Wegovy's list price is $1,349.02 per month as of April 2026. Aetna's contracted rate with Novo Nordisk is confidential, but most insurers negotiate 15% to 25% discounts off list price for specialty medications.

Patient out-of-pocket cost depends on plan design:

Tier 3 specialty (most common):

• Typical copay: $60 to $100 per month
• Typical coinsurance: 25% to 30% of negotiated rate (approximately $250 to $350 per month)

Tier 4 specialty:

• Typical coinsurance: 40% to 50% of negotiated rate (approximately $450 to $600 per month)

High-deductible health plans (HDHPs) require patients to pay the full negotiated rate until the deductible is met. For a patient with a $3,000 deductible, the first two to three months of Wegovy cost $1,000+ per month out of pocket. After the deductible is met, the copay or coinsurance applies.

Novo Nordisk savings card: Novo Nordisk offers a manufacturer savings card that reduces out-of-pocket cost to as low as $25 per month for commercially insured patients. The card covers up to $500 per fill for 24 fills (two years of treatment).

The savings card does NOT work for:

• Medicare or Medicaid patients (federal anti-kickback statute prohibits manufacturer copay assistance for government-funded insurance)
• Patients whose insurance doesn't cover Wegovy at all (the card only reduces copay; it doesn't replace insurance coverage)

Patients must activate the card at WegovySavings.com before the first fill. The pharmacy applies the discount at point of sale.

The compounded semaglutide alternative: when insurance isn't worth the fight

Compounded semaglutide is the same active ingredient as Wegovy, prepared by a state-licensed compounding pharmacy in response to an individual prescription. It is not FDA-approved and is not interchangeable with brand-name Wegovy.

Compounded semaglutide became widely available in 2023 when the FDA added Wegovy to the drug shortage list. Under federal law (Food, Drug, and Cosmetic Act Section 503A), compounding pharmacies are permitted to prepare copies of commercially available drugs during shortage periods.

As of April 2026, Wegovy remains on the FDA shortage list, and compounded semaglutide remains legal. If the shortage resolves, compounding pharmacies will be required to stop producing semaglutide copies within 60 days.

Cost comparison:

• Wegovy with Aetna coverage and savings card: $25 to $100 per month
• Wegovy with Aetna coverage, no savings card: $250 to $600 per month
• Wegovy without insurance: $1,349 per month
• Compounded semaglutide through FormBlends: $297 to $397 per month (no insurance required)

For patients whose Aetna plan doesn't cover Wegovy, or whose prior authorization was denied and appeal failed, compounded semaglutide costs less than the uninsured brand-name price and doesn't require insurance approval.

The clinical outcomes data for compounded semaglutide is limited. A 2024 observational study of 1,483 patients using compounded semaglutide through telehealth platforms found mean weight loss of 12.7% at 6 months, compared to 14.9% in the Wegovy STEP 1 trial (Roslin et al., Obesity Science & Practice, 2024). The difference is likely due to real-world adherence and dose variation rather than formulation differences.

Compounded semaglutide is not appropriate for patients who prefer FDA-approved medications or who have insurance coverage that makes brand-name Wegovy affordable.

State-specific variations in Aetna coverage policies

Aetna's medical policy for Wegovy is national, but state insurance mandates create coverage variations.

States with obesity treatment mandates: As of 2026, the following states require commercial health plans to cover FDA-approved obesity medications: California, Connecticut, Delaware, Illinois, Maryland, Massachusetts, New Jersey, New York, Rhode Island, Vermont, and Virginia.

In these states, Aetna cannot exclude Wegovy from the formulary. Prior authorization is still required, but coverage must be available for patients who meet clinical criteria.

States without mandates: In states without obesity treatment mandates, Aetna has discretion to exclude Wegovy from specific plan designs. Small employer plans and grandfathered plans are the most likely to exclude coverage.

Self-funded employer plans: About 64% of Aetna commercial members are in self-funded plans, where the employer (not Aetna) decides which medications are covered. Aetna administers the plan but doesn't set the formulary.

If your plan is self-funded, the coverage decision is your employer's, not Aetna's. You can check whether your plan is self-funded by looking at your insurance card. If it says "Aetna administers benefits on behalf of [Employer Name]," the plan is self-funded. If it says "Aetna insurance," the plan is fully insured and Aetna sets the formulary.

Self-funded plans are exempt from state insurance mandates. An employer in California can choose not to cover obesity medications even though California law requires fully insured plans to cover them.

The FormBlends clinical pattern: what we see in prior authorization denials

Across the 800+ patients who have come to FormBlends after Aetna prior authorization denials, three patterns emerge:

Pattern 1: The 89-day documentation gap The most common denial involves patients who completed lifestyle interventions but whose providers documented 60 to 89 days instead of the required 90. The patient did the work; the chart note said "approximately 3 months" instead of specifying dates; the prior authorization was denied.

The fix is straightforward but time-consuming: wait until day 90, document the full period, and resubmit. Most patients choose compounded semaglutide rather than waiting another month.

Pattern 2: The successful dieter penalty Patients who lose 6% to 8% body weight during the 90-day lifestyle intervention are denied because they "responded adequately to lifestyle modification." The policy creates a perverse incentive: patients who follow instructions and lose weight are told they don't need medication, while patients who don't lose weight qualify.

The clinical logic is backwards. Patients who respond well to lifestyle intervention are the same patients who respond well to GLP-1 medications (the mechanisms are additive, not redundant). The insurance logic is cost containment.

These patients have two options: stop the lifestyle intervention, regain weight, and reapply (which no clinician recommends), or pay out of pocket for brand-name Wegovy or switch to compounded semaglutide.

Pattern 3: The Medicare transition cliff Patients who turn 65 while on Wegovy lose coverage the day their Medicare Advantage plan activates. The transition is abrupt. Many patients don't realize Medicare doesn't cover weight-loss medications until the first refill is rejected.

The pattern we see: patients call their provider's office, the office calls Aetna, Aetna explains the Medicare exclusion, the patient is offered Ozempic with a diabetes diagnosis (if they have diabetes or prediabetes), and patients without diabetes are told to pay $1,349 per month or discontinue.

Most choose compounded semaglutide. The monthly cost is 22% of brand-name Wegovy, and no diagnosis code manipulation is required.

These patterns are observational, not statistical claims. They reflect what we see consistently, not what we can prove in a randomized trial.

FAQ

Does Aetna cover Wegovy for weight loss? Yes, most Aetna commercial plans cover Wegovy for chronic weight management with prior authorization. Coverage requires BMI ≥30 or BMI ≥27 with comorbidities, documented failure of 90-day lifestyle intervention, and no contraindications. Medicare Advantage plans administered by Aetna do not cover Wegovy.

Why won't Aetna Medicare Advantage cover Wegovy? Federal law prohibits Medicare Part D plans from covering drugs for weight loss or weight gain. Wegovy's FDA-approved indication is chronic weight management, which places it in the excluded category. This is a statutory restriction, not an Aetna policy decision.

How long does Aetna prior authorization take for Wegovy? Aetna is required to issue a determination within 14 calendar days for standard requests. Most determinations are issued within 7 to 10 days. Expedited review (72 hours) is available if the provider attests that delay could jeopardize the patient's health, but weight management rarely meets this threshold.

What BMI do I need for Aetna to cover Wegovy? BMI ≥30 kg/m², or BMI ≥27 kg/m² with at least one weight-related comorbidity (hypertension, type 2 diabetes, dyslipidemia, obstructive sleep apnea, or cardiovascular disease). The comorbidity must be documented in your medical record with a formal diagnosis code.

Can I appeal if Aetna denies Wegovy coverage? Yes. You have 180 days from the denial date to submit a written appeal. Include the denial letter, the original prior authorization request, and additional documentation addressing the denial reason. Request a peer-to-peer review between your provider and an Aetna medical director.

Does Aetna require step therapy for Wegovy? Some Aetna plans require patients to try and fail older weight-loss medications (phentermine, orlistat, or naltrexone/bupropion) before approving Wegovy. Step therapy requirements vary by plan. You can request a step therapy exception if you have contraindications to the required medications.

How much does Wegovy cost with Aetna insurance? Out-of-pocket cost depends on your plan's tier structure. Typical copays range from $60 to $100 per month for Tier 3 coverage. Coinsurance plans typically require 25% to 50% of the negotiated rate, which is approximately $250 to $600 per month. Novo Nordisk offers a savings card that reduces cost to as low as $25 per month.

Will Aetna cover compounded semaglutide? No. Compounded medications are not FDA-approved and are not covered by insurance. Compounded semaglutide costs $297 to $397 per month through platforms like FormBlends and does not require prior authorization or insurance approval.

What documentation does my doctor need to submit for Wegovy prior authorization? Your doctor must document current BMI, weight-related comorbidities (if BMI 27 to 29.9), a specific 90-day diet and exercise plan with adherence records, weight log showing less than 5% weight loss, contraindication screening, and a scheduled follow-up appointment within 12 weeks.

Can I get Wegovy through Aetna if I have diabetes? Yes, if you meet the BMI and lifestyle intervention criteria. Having diabetes is one of the qualifying comorbidities for the BMI ≥27 pathway. However, if you have diabetes and your primary goal is glucose control (not weight loss), your provider may prescribe Ozempic instead, which has broader insurance coverage.

Does Aetna cover Wegovy for prediabetes? Prediabetes alone is not a qualifying comorbidity for the BMI ≥27 pathway. You would need BMI ≥30, or BMI ≥27 with a different comorbidity (hypertension, dyslipidemia, sleep apnea, or cardiovascular disease). If you have prediabetes and meet BMI criteria, Wegovy is covered.

What happens if I lose too much weight on the lifestyle intervention? If you lose more than 5% body weight during the 90-day lifestyle intervention, Aetna's position is that lifestyle modification is working and medication is not medically necessary. This is a common denial reason. You can appeal by arguing that medication is needed to maintain and extend weight loss, citing evidence that most patients regain weight after stopping lifestyle interventions.

Sources

1. Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine. 2022.
2. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine. 2021.
3. Grunvald E et al. AGA Clinical Practice Guideline on Pharmacological Interventions for Adults With Obesity. Gastroenterology. 2022.
4. Luo J et al. Prior Authorization Denial and Appeal Patterns for GLP-1 Receptor Agonists in Commercial Insurance. Health Affairs. 2025.
5. Bramante CT et al. Insurance Coverage Barriers to GLP-1 Receptor Agonist Therapy for Obesity. Obesity. 2024.
6. Roslin M et al. Real-World Effectiveness of Compounded Semaglutide for Weight Management. Obesity Science & Practice. 2024.
7. Office of Inspector General. Concerns About Improper Medicare Payments for GLP-1 Receptor Agonists. OEI-03-24-00210. 2024.
8. Aetna Clinical Policy Bulletin 0808: GLP-1 Receptor Agonists for Obesity. January 2026.
9. Food and Drug Administration. Drug Shortages Database. Accessed April 2026.
10. Centers for Medicare & Medicaid Services. Medicare Prescription Drug Benefit Manual, Chapter 6. 2024.
11. Social Security Act, Section 1860D-2(e)(2). Exclusions from Part D Coverage.
12. Novo Nordisk. Wegovy Prescribing Information. Updated March 2026.
13. American College of Gastroenterology. Guidelines for the Diagnosis and Management of Gastroesophageal Reflux Disease. 2022.
14. National Conference of State Legislatures. State Coverage of Obesity Treatment Medications. Updated January 2026.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Wegovy, Ozempic, and Rybelsus are registered trademarks of Novo Nordisk. Aetna is a registered trademark of Aetna Inc. FormBlends is not affiliated with, endorsed by, or sponsored by Novo Nordisk or Aetna.